Darmultraschall und progressive transmurale Remission unter Anti-IL-12/23-Antikörper

被引:0
|
作者
Eduard F. Stange
机构
[1] Universitätsklinikum Tübingen,Klinik für Innere Medizin I
关键词
D O I
10.1007/s15036-023-3290-3
中图分类号
学科分类号
摘要
引用
收藏
页码:24 / 25
页数:1
相关论文
共 50 条
  • [1] Ansprechen auf Anti-IL12/23-Antikörper unter „Real-Life“-Bedingungen
    Eduard Stange
    Gastro-News, 2019, 6 (2) : 17 - 18
  • [2] Anti-Interleukin-12/23-Antikörper bei Colitis ulcerosa
    Manfred Gross
    Gastro-News, 2020, 7 (2) : 18 - 21
  • [4] Langfristige Remission unter Anti-IL12/23
    Beate Fessler
    Gastro-News, 2018, 5 (1) : 46 - 46
  • [5] Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease
    Khanna, Reena
    Preiss, Jan C.
    MacDonald, John K.
    Timmer, Antje
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2015, (05):
  • [6] Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease
    MacDonald, John K.
    Nguyen, Tran M.
    Khanna, Reena
    Timmer, Antje
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2016, (11):
  • [7] Anti-IL-12/23p40 antibodies for maintenance of remission in Crohn's disease
    Davies, Sarah C.
    Nguyen, Tran M.
    Parker, Claire E.
    MacDonald, John K.
    Jairath, Vipul
    Khanna, Reena
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2019, (12):
  • [8] Ingested (oral) anti-IL-12/23 inhibits EAE
    Brod, Staley A.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2016, 361 : 19 - 25
  • [9] Anti-IL-12/23: The Next Big Thing in IBD?
    Schwartz, David
    INFLAMMATORY BOWEL DISEASES, 2009, 15 (12) : 1927 - 1928
  • [10] Psoriatic arthritis and obesity: the role of anti-IL-12/IL-23 treatment
    Luisa Costa
    Roberta Ramonda
    Augusta Ortolan
    Marta Favero
    Rosario Foti
    Elisa Visalli
    Marco Rossato
    Fabio Cacciapaglia
    Giovanni Lapadula
    Raffaele Scarpa
    Clinical Rheumatology, 2019, 38 : 2355 - 2362